Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Einhorn, Cohen Cut Green Mountain Coffee $GMCR Stakes in 3rd Qtr

Green Mountain Coffee Roasters (GMCR) had a good run. In the first nine months of the year, GMCR rose from $34.45 a share on January 3 to close at $92.94 a share on September 30, but that was then.

David Einhorn’s Presentation Killed GMCR

Since the end of the third quarter, a lot has happened with GMCR. Since Greenlight Capital‘s David Einhorn criticized the company at the Value Investing Congress on October 17, GMCR’s shares have been sliding. Einhorn gave his presentation in the morning. By midday, the share price had fallen 11% (read about it here). Einhorn had explained, in a 110-slide presentation why he was shorting the company (see the presentation here). Afterwards, he explained to his investors in the quarterly letter (read it here) that much of his criticisms of the company were things that have happened over the last year. During the third quarter, Einhorn sold off roughly 400,000 GMCR shares, cutting his Greenlight Capital’s holding by around 42%.

David Einhorn

Steve Cohen and Patrick McCormack were on the Same Page

Steve Cohen, the founder and manager of SAC Capital, seems to agree with Einhorn. In the third quarter, Cohen reduced his fund’s shares in the company from roughly 1 million at the end of the second quarter to 630,000 at the close of the third quarter. Tiger Consumer Management’s Patrick McCormack reduced his shares in GMCR to 450,000, down roughly 30% from the second quarter. John Thaler’s JAT Capital Management and Philippe Lafont‘s Coatue Management also trimmed their GMCR positions during the third quarter.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!